These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 32423125)
21. Platelet function testing as a biomarker for efficacy of antiplatelet drugs. Lordkipanidzé M; So D; Tanguay JF Biomark Med; 2016 Aug; 10(8):903-18. PubMed ID: 27414976 [TBL] [Abstract][Full Text] [Related]
27. The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review. Pordzik J; Pisarz K; De Rosa S; Jones AD; Eyileten C; Indolfi C; Malek L; Postula M Front Endocrinol (Lausanne); 2018; 9():74. PubMed ID: 29615970 [TBL] [Abstract][Full Text] [Related]
28. Epigenetic Biomarkers and Cardiovascular Disease: Circulating MicroRNAs. de Gonzalo-Calvo D; Iglesias-Gutiérrez E; Llorente-Cortés V Rev Esp Cardiol (Engl Ed); 2017 Sep; 70(9):763-769. PubMed ID: 28623159 [TBL] [Abstract][Full Text] [Related]
29. Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes. Osman A; Fälker K Platelets; 2011; 22(6):433-41. PubMed ID: 21438667 [TBL] [Abstract][Full Text] [Related]
31. microRNAs in cardiovascular disease - clinical application. Schulte C; Karakas M; Zeller T Clin Chem Lab Med; 2017 May; 55(5):687-704. PubMed ID: 27914211 [TBL] [Abstract][Full Text] [Related]
32. Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS. Peng L; Liu J; Qin L; Liu J; Xi S; Lu C; Yin T Thromb Res; 2017 Sep; 157():97-102. PubMed ID: 28734158 [TBL] [Abstract][Full Text] [Related]
33. Association between microvesicles bearing monomeric C-reactive protein and platelet reactivity. Relationship with low response to antiplatelet drugs? Siennicka A J Physiol Pharmacol; 2021 Feb; 72(1):. PubMed ID: 34099580 [TBL] [Abstract][Full Text] [Related]
34. [Alteration in the expression of platelet microRNAs in diseases with abnormal platelet activation]. Fejes Z; Szilágyi B; Kappelmayer J; Ifj Nagy B Orv Hetil; 2018 Nov; 159(47):1962-1970. PubMed ID: 30474383 [TBL] [Abstract][Full Text] [Related]
35. MicroRNAs in platelet physiology and pathology. Dangwal S; Thum T Hamostaseologie; 2013; 33(1):17-20. PubMed ID: 23392306 [TBL] [Abstract][Full Text] [Related]
36. Modulation of microRNAs by aspirin in cardiovascular disease. Paseban M; Marjaneh RM; Banach M; Riahi MM; Bo S; Sahebkar A Trends Cardiovasc Med; 2020 Jul; 30(5):249-254. PubMed ID: 31444100 [TBL] [Abstract][Full Text] [Related]
37. Effects of antiplatelet therapy on platelet extracellular vesicle release and procoagulant activity in health and in cardiovascular disease. Connor DE; Ly K; Aslam A; Boland J; Low J; Jarvis S; Muller DW; Joseph JE Platelets; 2016 Dec; 27(8):805-811. PubMed ID: 27310292 [TBL] [Abstract][Full Text] [Related]
38. Platelet function testing in transient ischaemic attack and ischaemic stroke: A comprehensive systematic review of the literature. Lim ST; Coughlan CA; Murphy SJ; Fernandez-Cadenas I; Montaner J; Thijs V; Marquardt L; McCabe DJ Platelets; 2015; 26(5):402-12. PubMed ID: 26042726 [TBL] [Abstract][Full Text] [Related]
39. Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy. Tang QJ; Lei HP; Wu H; Chen JY; Deng CY; Sheng WS; Fu YH; Li XH; Lin YB; Han YL; Zhong SL Acta Pharmacol Sin; 2019 Feb; 40(2):208-215. PubMed ID: 29891858 [TBL] [Abstract][Full Text] [Related]
40. Plasma levels of platelet-enriched microRNAs change during antiplatelet therapy in healthy subjects. Krammer TL; Kollars M; Kyrle PA; Hackl M; Eichinger S; Traby L Front Pharmacol; 2022; 13():1078722. PubMed ID: 36578552 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]